mRNA and Delivery / Modified NTPs
N1-Methylpseudouridine-5'-Triphosphate
Quick view. N1-Methylpseudouridine-5'-Triphosphate is a modified uridine triphosphate for research-use nucleotide chemistry. CAS 1428903-59-6. Catalog target purity: Specification by inquiry. Availability: Inquiry only — contact OROGO to confirm current availability.
Request a quote Review request checklist
Catalog status
Scope. "Available for inquiry" is not a stock claim. Operating tier is a catalog-merchandising priority. Development phase and program context are shown only where the reviewed catalog source provides a mapping; they describe the chemistry platform and do not claim that OROGO supplies the named program.
| Supply status | Available for inquiry |
|---|---|
| Operating tier | Core |
| Reviewed supporting program count | 2 |
| Representative chemistry-platform program | Spikevax |
| Highest development phase | Marketed |
| CAS status | Published registry number |
Product profile
N1-Methylpseudouridine-5'-Triphosphate is classified as modified nucleoside triphosphate (Formula C10H17N2O15P3; molecular weight 498.17).
N1-Methylpseudouridine-5'-Triphosphate — Modified uridine triphosphate reagent for research workflows that specify the counterion-free N1-methylpseudouridine form.
For N1-Methylpseudouridine-5'-Triphosphate, modification benefits are context-dependent; transcript length, substitution level, enzyme system and analytical purity can change the observed outcome.
Names and search terms
Confirmed or normalized name variants
- N1-Methylpseudo-UTP
- m1Psi-5'-Triphosphate
Useful catalog search terms
- CAS 1428903-59-6
Physicochemical data
| Counterion | None in the controlling representation |
|---|---|
| PubChem CID | 90456815 |
| InChI | InChI=1S/C10H17N2O15P3/c1-12-2-4(9(15)11-10(12)16)8-7(14)6(13)5(25-8)3-24-29(20,21)27-30(22,23)26-28(17,18)19/h2,5-8,13-14H,3H2,1H3,(H,20,21)(H,22,23)(H,11,15,16)(H2,17,18,19)/t5-,6-,7-,8+/m1/s1 |
| InChIKey | OLRONOIBERDKRE-XUTVFYLZSA-N |
| SMILES | CN1C=C(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O |
Release documentation
The current specification defines the analytical method and acceptance criteria; the released lot result is reported on the CoA.
Additional HPLC, MS or NMR documentation can be agreed during technical review where available.
Product-specific evaluation notes
Potential advantages
- Base modifications can tune RNA stability, translation behavior, duplex properties or analytical discrimination versus native bases.
Method limitations
- Modification benefits are context-dependent; transcript length, substitution level, enzyme system and analytical purity can change the observed outcome.
These points describe N1-Methylpseudouridine-5'-Triphosphate or its named chemical feature. Broader product-family guidance is maintained on the category page.
Related products
Product-relevant literature
The publications below discuss named chemistry or a structural feature represented by this product. They provide scientific context only and are not an OROGO lot specification or product-performance claim.
- Human adipose-derived multipotent stromal cells enriched with IL-10 modRNA improve diabetic wound healing: Trigger the macrophage phenotype shift. (2025)
- Development of a retention prediction model in ion-pair reversed-phase HPLC for nucleoside triphosphates used as mRNA vaccine raw materials. (2022)
- Optimizing Cardiac Delivery of Modified mRNA. (2017)
Feature and workflow background
These publications discuss a broader chemistry feature or workflow identified from the catalog name or product family. They are background reading only, not evidence for the exact OROGO product, supplied form, lot specification, availability or performance.
Request a quote Review request checklist
Technology platforms
Catalog-derived platform membership for navigating related chemistry and verifiable product sets.